Ligand Pharmaceuticals and Glenmark Pharmaceuticals enters into license agreement
It is noteworthy that Ligand Pharmaceuticals entered into license agreement with Glenmark Pharmaceuticals to use Ligand’s OmniAb platform including Omnichicken, Omnirat, OmniMouse and OmniFlic to to discover fully human mono- and multispecific antibodies. Glenmark will bear all the program related costs.
John Higgins, Chief Executive Officer of Ligand said “This is the first new OmniAb partnership to include OmniChicken in addition to OmniRat, OmniMouse and OmniFlic. Ligand’s acquisition of OmniChicken demonstrated its commitment to provide the best antibody-discovery technologies to its current and future partners.”
Under the agreement, Ligand is liable for receiving annual platform access payments, development and regulatory milestone payments and tiered royalties for each product incorporating an OmniAb antibody.